Filing Flows › Impact Biomedical (IBO) › Q1 2026
Impact Biomedical (IBO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Impact Biomedical (IBO) reported revenue of $7K for the first quarter 2026 (Q1 2026) and 0% from the quarter before.
Impact Biomedical, Q1 2026: revenue $7K, net loss $2.3M, operating cash flow −$464K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7K | 0% | — |
| Operating profit | −$2.3M | — | — |
| Net earnings | −$2.3M | -144% | — |
| Operating cash flow | −$464K | -569% | — |
What changed
Revenue was $7K in Q1 2026, roughly flat from the previous quarter.
Operating costs exceeded revenue by $2.3M, an operating margin of -32700.0%. The quarter ended with a net loss of $2.3M, after a profit of $5.2M the previous quarter.
Operating cash flow was −$464K. Non-cash charges added back $285K of depreciation and amortization and $1.4M of share-based compensation. Working capital and other items added $95K.
Questions
What was Impact Biomedical's revenue in the first quarter 2026?
Impact Biomedical (IBO) reported revenue of $7K for the first quarter 2026 (Q1 2026) and 0% from the quarter before.
Source: Impact Biomedical 10-Q on SEC EDGAR.